Hospital market growth in the first half of the year again record low expectations superheroes

As the summer drew to a close, looking back at the pharmaceutical industry in the first half of 2018, compared with the turmoil in 2017, under the influence of comprehensive medical reform, generic drug consistency evaluation, economic and trade policies, the performance of the market terminal second- and third-level sample hospitals will be how?the overall market growth is slow, look forward to the second half of the adjustment
based on PDB domestic sample hospital market data, the first half of 2018, the overall market growth trend continues to maintain low operation. Specifically, due to the low starting point of 2017Q4, coupled with the weak growth of 2018Q1 and 2018Q2 compared with the same period last year, the growth rate of 2018H compared to the same period last year was only 0.98%, the first half of the growth rate in the last three years for the first time less than 1%. On this trend, if 2018Q3 does not see significant strength, the growth rate for the whole of 2018 will be a new low.traditional areas are weak and expect anti-infection and anti-tumor counter-attack
based on PDB domestic sample hospital market data, in the first half of 2018, the growth of the statistical amount TOP6 treatment field was found (in ATC-level classification), 2017 is a clear watershed. Compared with the same period last year, combined with the low growth rate of the overall market in the current period, in the first half of 2018, in addition to anti-tumor continued to maintain high growth, the recovery of anti-infective drugs is the most obvious, 5.07% growth rate, not only became six major areas of TOP1, but also got rid of the negative growth of the same period last year;leading varieties hold their ground and expect more new faces
based on PDB domestic sample hospital market data, the top 20 best-selling varieties in the first half of 2018 are as follows, compared to the first four in 2017 and the first half of 2017, the first four silks do not move, other varieties adjust significantly, the overall position fluctuations are greater. The best performers were Eso meprazole and Budinide, up 10 places from 2017 and 14 and 10 places from the first half of 2017, respectively, to 17th and 18th places respectively. At the same time, the ranking of neuroglycosides has fallen sharply, down 13 places from the 2017 full-year ranking, while complementary medications such as progestatrics and creatoic acid have fallen out of top 20 and the drug market may continue to contract in the second half of the year.The steady growth of multinational pharmaceutical companies, expect state-owned enterprises to reach a new high
based on PDB domestic sample hospital market data, the first half of 2018 the highest amount of 10 enterprises as follows, compared to 2017Q1 and 2017Q2, in addition to Qilu Pharmaceuticals, other enterprises are in the first quadrant, and foreign enterprises are concentrated in the 6% to 12% range, the growth trend is good. Qilu Pharmaceuticals' double negative growth rate continued to drop to No. 6 in the rankings, while the top-ranked Hengrui and Yangzijiang both maintained high growth. Also maintaining high growth in the first quadrant is Jiangsu Howson, although the current capacity is small, but the future development can be expected. (Medical Geography)